Early glaucoma vision test
Part of Eyes & vision clinical trials.
This study is testing a new way to detect early glaucoma by measuring how well you see. If you have early-stage glaucoma or healthy vision, your participation could help improve early diagnosis and treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (18 years or older).
- You either have early-stage glaucoma or you have healthy vision.
- Your vision must be correctable to 20/40 or better (meaning you can read a standard eye chart with glasses or contacts).
- You have no other eye, brain, or medical conditions (like epilepsy or macular degeneration) that could affect your performance on visual tests.
- You have not had any surgeries or injuries that affect your vision.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests new ways to evaluate eyes to help diagnose glaucoma and related eye conditions. You may be able to join if you’re an adult with normal eye health or with concerns like myopia, glaucoma suspicion, or ocular hypertension.
This study tests new ways to diagnose glaucoma (and sometimes related eye conditions) using eye exams and measurements. It may help improve how doctors detect glaucoma earlier and more accurately.
This study looks at different ways to measure how glaucoma affects your vision over time by comparing visual field results. It may help researchers find better models to track progression so treatment decisions can be made more accurately.
This trial compares different visual field test patterns to detect central vision loss in glaucoma patients who already show thinning of retinal cells. The goal is to find which test pattern works best for early detection.
This study tests a questionnaire and assessment tool to better understand how glaucoma affects everyday activities, and possibly driving readiness. It may help clinicians measure impact on daily living and monitor patient needs more clearly.
This study tests a new way to measure vision, called MLSDT, in people with normal sight or vision loss from Stargardt disease or geographic atrophy (a type of advanced age-related macular degeneration). Results will help doctors better understand how well patients can see.
Hear when a new Glaucoma Diagnosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.